CINECA IRIS Institutional Research Information System

BUDA, GABRIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.274
AS - Asia 5.796
EU - Europa 4.708
SA - Sud America 897
AF - Africa 268
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 8
Totale 23.972
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.936
SG - Singapore 1.784
IT - Italia 1.733
CN - Cina 1.626
HK - Hong Kong 951
BR - Brasile 721
SE - Svezia 701
DE - Germania 602
VN - Vietnam 490
BG - Bulgaria 353
GB - Regno Unito 274
TR - Turchia 252
CA - Canada 249
FR - Francia 239
RU - Federazione Russa 197
FI - Finlandia 178
IN - India 142
UA - Ucraina 130
JP - Giappone 129
CI - Costa d'Avorio 85
BD - Bangladesh 78
KR - Corea 62
CH - Svizzera 61
AR - Argentina 58
AT - Austria 54
IQ - Iraq 44
MX - Messico 39
ID - Indonesia 34
SN - Senegal 34
ZA - Sudafrica 34
SA - Arabia Saudita 31
PK - Pakistan 29
PL - Polonia 28
NL - Olanda 26
BE - Belgio 24
ES - Italia 24
MA - Marocco 23
VE - Venezuela 23
UZ - Uzbekistan 22
NG - Nigeria 21
CO - Colombia 20
EC - Ecuador 19
EG - Egitto 18
AU - Australia 17
CL - Cile 16
JM - Giamaica 14
KE - Kenya 13
CZ - Repubblica Ceca 12
PE - Perù 12
PY - Paraguay 12
AZ - Azerbaigian 11
CR - Costa Rica 11
IE - Irlanda 11
IL - Israele 11
AE - Emirati Arabi Uniti 10
MY - Malesia 10
BO - Bolivia 9
EE - Estonia 9
JO - Giordania 9
LT - Lituania 9
PH - Filippine 9
AL - Albania 7
OM - Oman 7
TH - Thailandia 7
TN - Tunisia 7
BJ - Benin 6
DZ - Algeria 6
EU - Europa 6
KG - Kirghizistan 6
NP - Nepal 6
PS - Palestinian Territory 6
RO - Romania 6
NI - Nicaragua 5
UY - Uruguay 5
AO - Angola 4
ET - Etiopia 4
HU - Ungheria 4
LV - Lettonia 4
PT - Portogallo 4
BN - Brunei Darussalam 3
DK - Danimarca 3
GR - Grecia 3
HN - Honduras 3
KZ - Kazakistan 3
LB - Libano 3
NZ - Nuova Zelanda 3
RS - Serbia 3
TT - Trinidad e Tobago 3
BS - Bahamas 2
DO - Repubblica Dominicana 2
GD - Grenada 2
GY - Guiana 2
IR - Iran 2
KH - Cambogia 2
LY - Libia 2
MN - Mongolia 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TG - Togo 2
TW - Taiwan 2
Totale 23.934
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.283
Ashburn 1.159
Singapore 1.005
Hong Kong 939
Fairfield 936
San Jose 747
Ann Arbor 745
Santa Clara 727
Chandler 644
Dallas 643
Houston 608
Serra 523
Milan 474
Seattle 431
Beijing 415
Wilmington 372
Shanghai 365
Sofia 351
Cambridge 332
New York 269
Boardman 251
Los Angeles 205
Ottawa 193
Princeton 182
Jacksonville 178
Florence 162
Izmir 143
Lawrence 142
Medford 137
Lauterbourg 135
Ho Chi Minh City 120
Munich 119
Tokyo 115
Nanjing 106
Hefei 100
Hanoi 90
Abidjan 85
Istanbul 83
Des Moines 81
Frankfurt am Main 71
London 63
Seoul 62
Buffalo 61
Rome 59
São Paulo 59
Dong Ket 58
Council Bluffs 55
Bremen 54
Redondo Beach 54
San Diego 51
Dearborn 49
Pisa 49
Bern 47
Helsinki 42
Vienna 40
Redwood City 36
Turku 35
Dakar 34
Nanchang 32
Changsha 30
Hebei 30
Dhaka 28
Shenyang 28
Boulder 26
Nuremberg 26
Lancaster 25
Brussels 24
Jüchen 24
Da Nang 23
Orem 23
Düsseldorf 22
Ogden 22
Chicago 20
Kunming 20
Lagos 20
Tashkent 20
Warsaw 20
Fuzhou 19
Jiaxing 19
Belo Horizonte 18
Chennai 18
Columbus 18
Guangzhou 18
San Francisco 18
Phoenix 17
Rio de Janeiro 17
The Dalles 17
Manchester 16
Baghdad 15
Baltimore 15
Denver 14
Jakarta 14
Norwalk 14
Stockholm 14
Lucca 13
Nürnberg 13
Porto Alegre 13
Toronto 13
Curitiba 12
Hyderabad 12
Totale 17.394
Salva come PNG Salva come JPEG
Nome #
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk 249
Atypical APL including multiple translocations and abnormal response to micronuclei induction test 246
Identification of miRSNPs associated with the risk of multiple myeloma 237
CD45 expression in low-grade B-cell non-Hodgkin's lymphomas 233
Bone marrow infiltration in B-cell non-Hodgkin's lymphomas: comparison between flow cytometry and bone marrow biopsy, RECENTI PROGRESSI IN MEDICINA 231
Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. 220
CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUM- AB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE 216
Infliximab treatment of grade IV skin acute graft versus host disease 215
Could age modify the effect of genetic variants in IL6 and TNF-a genes in multiple myeloma? 211
Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. 211
CD229 expression on bone marrow plasma cells from patients with multiple myeloma and monoclonal gammopathies of uncertain significance 211
EFFICACY OF FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (FCR) REGIMEN FOL- LOWED BY ALEMTUZUMAB AS IN VIVO PURGING TOOL FOR PATIENTS WITH ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA 207
Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms 205
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. 204
Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). 202
Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. 202
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 202
Dipeptidyl-Peptidase 4 (Cd26): a Possible Therapeutic Target in Covid-19 202
Unexpected cardiotoxicity in haematological bortezomib treated patients 194
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). 194
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 192
Role of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkin’s Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen. 188
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma 188
Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma 188
Association of PIM gene translocation and TELAML1 rearrangement., LEUKEMIA RESEARCH,vol. Leuk Res. 2007 Dec;31(12):1761-2 185
Vascular Endothelial Growth Factor Polymorphisms in Mantle Cell Lymphoma 184
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. 2010 Apr;21(4):851-4. Epub 2009 Oct 13. 183
Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortium. 183
VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients 183
ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT 183
INDUCTION OF COMPLETE MOLECULAR RESPONSE WITH YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN®) IN B CELL NON HODGKIN’S LYMPHOMA PATIENTS AFTER THE ACHIEVEMENT OF A COMPLETE CLINICAL RESPONSE WITH CHEMOTHERAPY REGIMEN 182
Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization 182
Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib 182
Myelomatous meningitis evaluated by multiparameter flow cytometry : report of a case and review of the literature 180
High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naïve lymphocytes and prevents TTV reactivation 180
Aggressive Non Hodgkin lymphoma'patients Treated by High Dose Chemotherapy and Immunotherapy Has a Lower Relapse Rate: Results of a Computer Science Analysis. 175
Folic acid fortification and cancer risk 173
A therapy resistant myelodysplastic syndrome characterized by the presence of the rare reciprocal translocation t(3;12)(q26.2;p13) 172
Piezoelectric signals in vascularized bone regeneration 172
Pharmacogenetic Study on Multiple Myeloma Patients Treated with DAV Regimen and Autologous Stem Cell Transplantation. 171
Immune Reconstitution after Allogeneic Stem Cell Transplantation: a Pilot Flow-Cytometry Study for T-Cell Sub-Populations 171
Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk 170
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma 169
A whole blood flow cytometric method to evaluate F-actin polymerization in neutrophils 168
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) POLYMORPHISMS AND THEIR RELATIONSHIP WITH CLINICAL OUTCOME OF MANTLE CELL LYMPHOMA 168
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients 168
Unusual association of endometrial cancer and multiple myeloma 168
Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia 168
Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study 168
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 167
MDR1 polymorphism influences the outcome of multiple myeloma patients 166
ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT 166
Other mechanisms to explain the role of reduced folate carrier in cancer 165
Donor-transmitted Triple-Hit Lymphoma in a Renal Allograft Recipient 163
CD69, a New Potential Clinical Marker in Multiple Myeloma 162
Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients 161
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 161
Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation 159
NQO1*2 polymorphism and response to treatment in patients with multiple myeloma 158
Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. 158
ZINC ORAL SUPPLEMENTATION INDUCES A SIGNIFICANT RISE OF TRECS AND T CD4+ NAΪVE AND PREVENTS THE INCREASE OF TTV VIRAL LOAD AFTER STEM CELL TRANSPLANTATION: THE ZENITH STUDY 158
CD69 Expression Predicts Favorable Outcome in Multiple Myeloma Patients Treated with VTD 157
The Onset of Monoclonal and Oligoclonal Gammopathies Is a Good Prognostic Factor after Allogeneic Stem Cell Transplantation 157
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients 156
TNF-a Polymorphism Modulates the Outcome of Multiple Myeloma Patients Treated with Bortezomib 155
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in ch 154
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. 154
MDR1 polymorphism influences the outcome of multiple myeloma patients 151
Free light chains are needed for the follow up of multiple myeloma 151
The onset of monoclonal and oligoclonal gammopathies is a good prognostic factor after allogeneic stem cell transplantation 151
Two Cases of Plasma Cell Leukemia with Atypical Immunophenotype 150
Poor prognosis chronic myeloid leukemia with a complex variant Philadelphia translocation, t(9;10;22)(q34;q24;q11) 149
PRDI-BF1 and PRDI-BF1P isoform expressions correlate with disease status in multiple myeloma patients 149
Neoplasie degli organi emopoietici e linfatici: peculiarità dell'anziano 149
[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions 149
Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia 146
Association of PIM gene translocation and TEL/AML1 rearrangement. 146
A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis 146
Safety and Efficacy of Pegylated Liposomal Doxorubicin In Combination with Dexamethasone and Bortezomib (VMD) or Lenalidomide (RMD) In Multiple Myeloma Refractory/Relapsed Patients 146
Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era. 146
Folate levels in cancer: a vitamin for a new challenge 145
Comparison of Bone Marrow Biopsy, Flow Cytometry and PCR Assays To Detect Bone Marrow Involvement in B-Cell Non-Hodgkin Lymphomas. 144
Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. 144
Cardiac light-chain deposition disease relapsing in the transplanted heart 144
Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients 144
CD45 expression in low-grade non-Hodgkin's lymphomas 143
ORAL CYCLOPHOSPHAMIDE AND RITUXIMAB IN THE TREATMENT OF MARGINAL ZONE LYMPHOMA 143
MDR1 modulates apoptosis in CD34+ leukemic cells 141
Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia 141
A polygenic risk score for multiple myeloma risk prediction 141
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 141
Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myeloma 140
Stable low IgG levels in relapsed non-Hodgkin's lymphomas 140
MDR1 diplotypes as prognostic markers in multiple myeloma 140
Molecular Remission After VTD or TAD As Induction for Multiple Myeloma: Results with Two Different Methods of Analysis 140
Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. 140
Identification of novel genetic loci for risk of multiple myeloma by functional annotation 139
Optimizing Follow up Schedule for Non Hodgkin Lymphoma' Patients by Multi-Objective Analysis. 139
Plasma Cell Disorders and Dialysis-Dependent Renal Failure: Safety and Efficacy of Autologous Stem Cell Transplantation 139
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization 138
Totale 17.068
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.669
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.669
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021194 0 0 0 0 0 0 0 0 0 0 0 194
2021/20221.647 44 103 53 103 273 199 59 68 89 59 118 479
2022/20232.110 291 289 136 183 211 229 18 167 345 14 208 19
2023/20241.680 193 215 218 138 267 243 65 35 16 27 97 166
2024/20255.204 19 175 49 290 487 506 439 266 498 638 519 1.318
2025/20265.709 378 649 738 494 652 531 892 221 308 552 207 87
Totale 24.283